Successful use of trastuzumab deruxtecan in hepatic visceral crisis secondary to metastatic HER2-low breast cancer

•Up to 20 % of patients with metastatic breast cancer develop hepatic visceral crisis, a life-threatening condition that implies impending liver failure and death.•Combination chemotherapy is recommended for hepatic visceral crisis however the outcomes are generally dismal.•Trastuzumab deruxtecan is...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Current problems in cancer. Case reports Jg. 20; S. 100392
Hauptverfasser:	Kapoor, Nilesh, Su, Malcolm, Horadam, Rochelle, Klemow, Dawn, Syed, Samira
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Elsevier Inc 01.12.2025
Schlagworte:	Antibody-drug conjugate Hematology, Oncology, and Palliative Medicine Hepatic visceral crisis HER2-low Metastatic breast cancer Trastuzumab deruxtecan Metastatic breast cancer HER2-low Trastuzumab deruxtecan Hepatic visceral crisis Antibody-drug conjugate
ISSN:	2666-6219, 2666-6219
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!